Introduction:
The Kerala High Court on August 21, 2026, took another significant step in its continuing examination of the high cost of life-saving patented medicines by allowing a breast cancer patient, who is presently undergoing treatment with Ribociclib, to be impleaded as an additional respondent in a suo motu proceeding concerning the exorbitant pricing of certain patented breast cancer drugs. The matter, titled In Re Exorbitant Pricing of Life Saving Patented Medicines, has developed into an important judicial examination of the relationship between patent rights, pharmaceutical pricing, public health and the constitutional imperative of ensuring meaningful access to essential treatment.
Justice Harisankar V. Menon allowed the impleadment application and posted the matter for final consideration on September 3, 2026. Taking note of the urgency highlighted by amicus curiae Maitreyi Sachidananda Hegde and the Supreme Court’s request that the matter be disposed of expeditiously, the Court also directed the Additional Solicitor General of India, P. Sreekumar, to coordinate with the institutions suo motu impleaded earlier and ensure that their statements or affidavits were placed on record before the next hearing.
The proceedings had originally commenced on the plea of another breast cancer patient who was being treated with Ribociclib, a patented medicine used in the treatment of certain forms of breast cancer. She had approached the Kerala High Court seeking intervention by the Central Government under the provisions of the Patents Act, 1970. Her case raised a fundamental concern: when a life-saving patented medicine is priced beyond the reach of many patients, what legal powers are available to the Government to protect public health and ensure wider access to treatment?
The original petitioner had specifically referred to Sections 83, 92 and 100 of the Patents Act. Section 83 lays down the general principles applicable to the working of patented inventions in India and reflects the legislative philosophy that patent rights are not intended to operate merely as private monopolies divorced from the larger public interest. The provision emphasises, among other things, that patents should promote technological innovation and ensure that patented inventions are available to the public at reasonably affordable prices.
Section 92 deals with the grant of compulsory licences in circumstances of national emergency, extreme urgency or public non-commercial use. The provision allows the Central Government to make a declaration in appropriate circumstances, following which compulsory licences may be granted for relevant patented inventions. Such a mechanism recognises that patent protection, though legally valuable and essential to encourage innovation, may sometimes have to yield to compelling public health requirements.
Section 100 provides another significant governmental power by authorising the Central Government, or a person authorised by it, to use a patented invention for the purposes of the Government. In situations involving extreme necessity and access to life-saving medicines, this provision assumes particular importance because it offers a possible statutory route through which the Government may respond to urgent public requirements.
During the pendency of the proceedings, however, the original petitioner passed away. Rather than allowing the larger issue to disappear with the individual cause of action, the Kerala High Court decided to continue examining the matter as a suo motu case. This decision transformed what began as one patient’s struggle for access to affordable treatment into a broader judicial inquiry concerning a question capable of affecting numerous cancer patients.
The current proceedings are particularly concerned with the pricing and accessibility of Ribociclib and Abemaciclib, patented medicines used in the treatment of breast cancer. The Court has been examining whether there are legally and medically viable alternatives available to patients who cannot afford these drugs. Last month, after hearing the amicus curiae and counsel appearing for the Union Government and pharmaceutical companies, the Court sought expert assistance on a crucial medical question: whether Palbociclib, a comparatively cheaper medicine that is no longer protected by patent and is also manufactured locally, can serve as a substitute for Ribociclib and Abemaciclib.
The answer to this question has become central to the case. If Palbociclib can be considered a therapeutically suitable substitute in relevant cases, the issue of access may require one set of policy and legal responses. If, however, it cannot be treated as a genuine substitute, patients who medically require patented Ribociclib or Abemaciclib may remain dependent upon drugs available at prices that are allegedly beyond the reach of many.
Recognising that this issue could not be decided on legal submissions alone, the Court had earlier suo motu impleaded the National Cancer Institute at Jhajjar, the Chittaranjan National Cancer Institute in Kolkata, the Regional Cancer Centre in Thiruvananthapuram and the Drugs Controller General of India. Their participation was intended to provide the Court with informed scientific and regulatory perspectives on the question of therapeutic interchangeability.
The subsequent impleadment application filed by a breast cancer patient presently taking Ribociclib gave the proceedings an immediate human dimension. Unlike an abstract debate on patent policy, the Court was now confronted with the circumstances of an affected patient who was directly dependent on one of the medicines under consideration. Allowing her to participate ensured that the perspective of patients living with the consequences of high drug prices would remain before the Court during the final hearing.
The case therefore stands at the intersection of several competing interests. Pharmaceutical companies have statutory patent rights designed to reward innovation and investment in research. The Government has obligations relating to public health and access to essential medicines. Medical experts must determine whether one drug can safely and effectively replace another for particular patients. Most importantly, patients facing serious illnesses require treatment decisions that cannot be reduced to economic considerations alone.
It is against this background that the Kerala High Court’s order assumes wider significance. The Court did not attempt to prescribe a medical treatment or itself decide whether Palbociclib is interchangeable with Ribociclib. Instead, it sought expert evidence, brought affected stakeholders before it and accelerated the matter for final consideration. The approach reflects judicial recognition that access to life-saving medicines is not merely a question of patent law but one that implicates dignity, health, equality and the practical ability of patients to benefit from advances in medical science.
Arguments of the Parties:
The case before the Kerala High Court involves a broad range of submissions because the central issue cannot be resolved by applying patent law in isolation. The original proceedings were initiated by a breast cancer patient who sought governmental intervention after being required to undergo treatment with patented Ribociclib. Her plea was based on the concern that the price of the medicine was so high that access to treatment was severely restricted for patients who could not afford it.
The petitioner’s underlying argument was that the grant of a patent does not create an absolute and unrestricted right to commercially exploit a medicine without regard to public interest. The Patents Act itself contains safeguards that recognise the special nature of pharmaceutical inventions. Section 83, in particular, reflects the principle that patent protection must operate in a manner consistent with public welfare and that patented inventions should be available at reasonably affordable prices.
The petitioner had therefore sought consideration of statutory mechanisms available to the Central Government under Sections 92 and 100 of the Patents Act. The argument was not simply that a patented medicine was expensive, but that the circumstances warranted serious governmental consideration of whether extraordinary legal measures could be used to expand access to a life-saving treatment.
The plea also raised the broader question of whether the existing price and supply situation was compatible with the public interest principles underlying the patent regime. A patient suffering from a serious and potentially life-threatening illness may not have the luxury of waiting for market forces to reduce prices or for a patent to expire. Where treatment is medically necessary and there is no equally effective alternative, the affordability of the medicine can become a matter of survival.
After the death of the original petitioner and the conversion of the matter into a suo motu proceeding, amicus curiae Maitreyi Sachidananda Hegde continued to assist the Court on the broader legal and public health questions. The urgency of the matter was repeatedly emphasised, particularly because the issue affects patients presently undergoing treatment and not merely future consumers of medicines.
The amicus also raised an important concern regarding the affidavit filed on behalf of the Drugs Controller General. According to the point recorded by the Court, the affidavit did not conclusively state that Palbociclib was a substitute for Ribociclib. This was significant because the availability of a cheaper medicine does not automatically establish that every patient can safely be shifted to it.
The Drugs Controller’s affidavit indicated that the question of therapeutic interchangeability between the two medicines for a particular patient should be determined by the treating doctor or oncologist. From the perspective of the regulatory authorities, this reflects an important medical principle. Different medicines may belong to a similar therapeutic class and may be used for broadly similar conditions, yet their suitability can depend upon a patient’s individual medical profile, the stage and characteristics of the disease, previous treatment and other clinical factors.
The position of the medical and regulatory respondents therefore required the Court to distinguish between general availability and actual interchangeability. It may not be enough to say that a cheaper drug exists in the market. The relevant question is whether that drug can medically replace the patented medicine for the particular category of patients who require it.
The Union Government and its counsel were also required to respond to the statutory and policy questions raised in the proceedings. The Government possesses powers under the Patents Act, but the exercise of those powers involves consideration of legal conditions, public interest and the factual circumstances of the case. Compulsory licensing and government use are exceptional statutory mechanisms, and the question before the Court is whether the situation surrounding access to the concerned breast cancer medicines warrants governmental intervention.
The pharmaceutical companies, represented by senior counsel, are likely to maintain that patent protection is a legitimate statutory right granted to encourage pharmaceutical research and innovation. The development of new medicines requires extensive investment, scientific research, clinical trials and regulatory compliance. Patent protection provides a time-limited period during which innovators can recover investments and continue funding future research.
From this perspective, the companies may also contend that judicial intervention in drug pricing or the exercise of extraordinary patent powers must be based on clear statutory and factual grounds. The mere fact that a patented medicine is expensive, they may argue, cannot automatically justify compulsory licensing or government use. The legal requirements prescribed under the Patents Act must be satisfied, and the medical and market circumstances must be carefully examined.
The pharmaceutical side may further emphasise that questions concerning the suitability of Palbociclib as an alternative are fundamentally matters of scientific and clinical expertise. Courts should not independently determine therapeutic equivalence without reliable evidence from qualified oncologists, cancer institutes and regulatory authorities. The Court’s decision to seek expert opinions and affidavits from specialised institutions is therefore consistent with the need for decisions affecting patient treatment to rest on medical evidence rather than assumptions.
The newly impleaded breast cancer patient brings another perspective to the proceedings. As a person currently taking Ribociclib, her participation demonstrates that the issue is not academic. For an affected patient, the cost of a medicine may directly determine whether a prescribed treatment can be continued. Her impleadment also enables the Court to consider the real-world impact of pricing and availability on those who are currently dependent upon patented medicines.
The opposing positions, therefore, reveal the complexity of the dispute. Patients and public health advocates emphasise affordability and the need to ensure that no person is effectively denied essential treatment because of prohibitive prices. Patent holders emphasise the legal rights attached to innovation and caution against extraordinary interference without satisfying statutory requirements. The Government and regulatory bodies must address whether the circumstances justify intervention, while medical experts must answer whether cheaper alternatives are genuinely suitable.
The immediate controversy over Palbociclib illustrates why the Court has sought additional material. If it is established that Palbociclib can safely and effectively substitute Ribociclib for relevant patients, the argument for extraordinary intervention may require a different assessment. But if medical evidence establishes that it is not an equivalent substitute in material circumstances, the affordability crisis surrounding the patented medicines may become more acute.
The Court’s oral observation captured the importance of this factual determination: the key question is whether the cheaper medicine is truly a substitute. The observation that, if it is not a substitute, the Court may perhaps issue a direction to the Central Government indicates that the medical answer could directly influence the legal consequences considered by the Court.
Court’s Judgment:
Justice Harisankar V. Menon allowed the impleadment petition filed by the breast cancer patient who is presently undergoing treatment with Ribociclib. The Court’s decision recognised that an affected patient has a direct and substantial interest in the outcome of proceedings concerning the accessibility and affordability of the medicine on which she is currently dependent.
The impleadment is particularly significant because the original patient who initiated the litigation had died during the pendency of the case. By converting the matter into a suo motu proceeding, the Court had already recognised that the questions raised transcended the circumstances of one individual. Allowing another patient to participate further strengthened the representative and public-interest character of the proceedings.
The Court also posted the matter for final consideration on September 3, 2026. This expedited schedule was adopted in view of the urgency highlighted by the amicus curiae and the Supreme Court’s request that the Kerala High Court dispose of the matter expeditiously. The order referred to the Supreme Court’s direction dated July 17, 2026, in Suo Motu Writ Petition (Civil) No. 19 of 2026.
The High Court further noted that, at that stage, an affidavit had been filed only on behalf of the Drugs Controller General. The other specialised institutions that had been suo motu impleaded had not yet placed their responses on record. The Court consequently directed the Additional Solicitor General of India, P. Sreekumar, to liaise with the National Cancer Institute, the Chittaranjan National Cancer Institute and the Regional Cancer Centre and ensure that statements or affidavits were filed before the next date of hearing.
This direction demonstrates the Court’s determination to obtain the necessary medical expertise before arriving at a final decision. The question before the Court is not one that can be answered through legal interpretation alone. Whether Palbociclib is a therapeutic substitute for Ribociclib or Abemaciclib involves specialised scientific considerations, and the Court has therefore sought assistance from institutions directly engaged in cancer treatment and research.
The most important reasoning emerging from the order concerns the distinction between the existence of an alternative medicine and its actual therapeutic interchangeability. The affidavit of the Drugs Controller General did not conclusively state that Palbociclib was a substitute for Ribociclib. Instead, it indicated that the question of interchangeability for a particular patient must be decided by the treating doctor or oncologist.
The Court treated this issue as central to the final resolution of the case. Its oral observation that “the only question is whether this is a substitute or not” demonstrates that the Court sees the medical evidence as a decisive foundation for determining the appropriate legal response. If the cheaper medicine is a genuine and medically acceptable substitute, the nature of the access problem may be different. If it is not, the Court may need to examine whether the Central Government should be directed to consider the statutory powers available to it.
The Court’s further observation that it would “find a solution” must be understood within the limits of judicial power. The Court has not itself invoked Section 92 or Section 100 of the Patents Act, nor has it directed the immediate grant of a compulsory licence. Rather, it has kept open the possibility of issuing directions to the Central Government after the relevant facts, expert opinions and legal submissions are fully placed before it.
The legal principles involved are rooted in the broader architecture of the Patents Act. Section 83 makes clear that the patent system in India is not based solely on the protection of private commercial interests. Patents are granted to encourage inventions, but the statutory framework also seeks to ensure that technological benefits reach the public and that patented inventions are available at reasonably affordable prices.
This balance is especially significant in the pharmaceutical sector. The right of an innovator to enjoy patent protection must be viewed alongside the consequences for patients when the patented invention is a medicine necessary for treating a serious disease. The Patents Act itself provides mechanisms through which the public interest can be protected in exceptional circumstances.
Section 92 is one such mechanism. In circumstances of national emergency, extreme urgency or public non-commercial use, the Central Government may take steps that facilitate compulsory licensing. The provision is not an ordinary pricing control mechanism, but it reflects Parliament’s recognition that extraordinary public needs may justify intervention in the exclusive rights ordinarily attached to a patent.
Section 100 similarly enables the Government to use a patented invention for governmental purposes, subject to the statutory framework. In the context of life-saving medicines, the provision may become relevant where governmental action is required to respond to an urgent public halth need.
The Court’s approach also reflect